ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could estrogen shrink some triple negative breast tumors?
Disease control OngoingThis phase II trial at Mayo Clinic tests whether estradiol, a form of estrogen, can help patients with a specific subtype of triple negative breast cancer that has a receptor called ER beta. The study enrolls 8 women with advanced or metastatic disease. Researchers will measure h…
Matched conditions: ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Wheat germ supplement studied for immune boost in advanced cancer
Knowledge-focused TerminatedThis study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…
Matched conditions: ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jul 02, 2026 02:00 UTC